249 related articles for article (PubMed ID: 33887357)
1. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.
Vallejo A; Erice O; Entrialgo-Cadierno R; Feliu I; Guruceaga E; Perugorria MJ; Olaizola P; Muggli A; Macaya I; O'Dell M; Ruiz-Fernandez de Cordoba B; Ortiz-Espinosa S; Hezel AF; Arozarena I; Lecanda F; Avila MA; Fernandez-Barrena MG; Evert M; Ponz-Sarvise M; Calvisi DF; Banales JM; Vicent S
J Hepatol; 2021 Aug; 75(2):363-376. PubMed ID: 33887357
[TBL] [Abstract][Full Text] [Related]
2. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.
Vallejo A; Perurena N; Guruceaga E; Mazur PK; Martinez-Canarias S; Zandueta C; Valencia K; Arricibita A; Gwinn D; Sayles LC; Chuang CH; Guembe L; Bailey P; Chang DK; Biankin A; Ponz-Sarvise M; Andersen JB; Khatri P; Bozec A; Sweet-Cordero EA; Sage J; Lecanda F; Vicent S
Nat Commun; 2017 Feb; 8():14294. PubMed ID: 28220783
[TBL] [Abstract][Full Text] [Related]
3. PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice.
Yang Y; Wang J; Wan J; Cheng Q; Cheng Z; Zhou X; Wang O; Shi K; Wang L; Wang B; Zhu X; Chen J; Feng D; Liu Y; Jahan-Mihan Y; Haddock AN; Edenfield BH; Peng G; Hohenstein JD; McCabe CE; O'Brien DR; Wang C; Ilyas SI; Jiang L; Torbenson MS; Wang H; Nakhleh RE; Shi X; Wang Y; Bi Y; Gores GJ; Patel T; Ji B
J Hepatol; 2024 Jul; 81(1):120-134. PubMed ID: 38428643
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-27a-3p targets FoxO signalling to induce tumour-like phenotypes in bile duct cells.
Duwe L; Munoz-Garrido P; Lewinska M; Lafuente-Barquero J; Satriano L; Høgdall D; Taranta A; Nielsen BS; Ghazal A; Matter MS; Banales JM; Aldana BI; Gao YT; Marquardt JU; Roberts LR; Oliveira RC; Koshiol J; O'Rourke CJ; Andersen JB
J Hepatol; 2023 Feb; 78(2):364-375. PubMed ID: 36848245
[TBL] [Abstract][Full Text] [Related]
5. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.
Merino-Azpitarte M; Lozano E; Perugorria MJ; Esparza-Baquer A; Erice O; Santos-Laso Á; O'Rourke CJ; Andersen JB; Jiménez-Agüero R; Lacasta A; D'Amato M; Briz Ó; Jalan-Sakrikar N; Huebert RC; Thelen KM; Gradilone SA; Aransay AM; Lavín JL; Fernández-Barrena MG; Matheu A; Marzioni M; Gores GJ; Bujanda L; Marin JJG; Banales JM
J Hepatol; 2017 Jul; 67(1):72-83. PubMed ID: 28237397
[TBL] [Abstract][Full Text] [Related]
6. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.
Olaizola P; Lee-Law PY; Fernandez-Barrena MG; Alvarez L; Cadamuro M; Azkargorta M; O'Rourke CJ; Caballero-Camino FJ; Olaizola I; Macias RIR; Marin JJG; Serrano-Maciá M; Martinez-Chantar ML; Avila MA; Aspichueta P; Calvisi DF; Evert M; Fabris L; Castro RE; Elortza F; Andersen JB; Bujanda L; Rodrigues PM; Perugorria MJ; Banales JM
J Hepatol; 2022 Jul; 77(1):177-190. PubMed ID: 35217064
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
8. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma.
Xu Y; Yao Y; Jiang X; Zhong X; Wang Z; Li C; Kang P; Leng K; Ji D; Li Z; Huang L; Qin W; Cui Y
J Exp Clin Cancer Res; 2018 Apr; 37(1):81. PubMed ID: 29642935
[TBL] [Abstract][Full Text] [Related]
9. SOX2 knockdown slows cholangiocarcinoma progression through inhibition of transcriptional activation of lncRNA PVT1.
Yu A; Zhao L; Kang Q; Li J; Chen K; Fu H
Biochem J; 2020 Sep; 477(18):3527-3540. PubMed ID: 32812642
[TBL] [Abstract][Full Text] [Related]
10. LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma.
Conboy CB; Yonkus JA; Buckarma EH; Mun DG; Werneburg NW; Watkins RD; Alva-Ruiz R; Tomlinson JL; Guo Y; Wang J; O'Brien D; McCabe CE; Jessen E; Graham RP; Buijsman RC; Vu D; de Man J; Ilyas SI; Truty MJ; Borad M; Pandey A; Gores GJ; Smoot RL
J Hepatol; 2023 Jan; 78(1):142-152. PubMed ID: 36162702
[TBL] [Abstract][Full Text] [Related]
11. Transcription factor 7 promotes the progression of perihilar cholangiocarcinoma by inducing the transcription of c-Myc and FOS-like antigen 1.
Liu Z; Sun R; Zhang X; Qiu B; Chen T; Li Z; Xu Y; Zhang Z
EBioMedicine; 2019 Jul; 45():181-191. PubMed ID: 31248836
[TBL] [Abstract][Full Text] [Related]
12. Identification of transcription factors (TFs) and targets involved in the cholangiocarcinoma (CCA) by integrated analysis.
Yang L; Feng S; Yang Y
Cancer Gene Ther; 2016 Dec; 23(12):439-445. PubMed ID: 27857060
[TBL] [Abstract][Full Text] [Related]
13. Animal models of cholangiocarcinoma.
Loeuillard E; Fischbach SR; Gores GJ; Ilyas SI
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):982-992. PubMed ID: 29627364
[TBL] [Abstract][Full Text] [Related]
14. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
[TBL] [Abstract][Full Text] [Related]
15. Circ-LAMP1 contributes to the growth and metastasis of cholangiocarcinoma via miR-556-5p and miR-567 mediated YY1 activation.
Xu Y; Gao P; Wang Z; Su Z; Liao G; Han Y; Cui Y; Yao Y; Zhong X
J Cell Mol Med; 2021 Apr; 25(7):3226-3238. PubMed ID: 33675150
[TBL] [Abstract][Full Text] [Related]
16. Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth.
Li Y; Cai Q; Li W; Feng F; Yang L
Biochem Biophys Res Commun; 2018 Oct; 504(4):654-659. PubMed ID: 30205958
[TBL] [Abstract][Full Text] [Related]
17. All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS.
Vallejo A; Valencia K; Vicent S
Mol Cell Oncol; 2017; 4(3):e1314239. PubMed ID: 28616588
[No Abstract] [Full Text] [Related]
18. Genetics of Opisthorchis viverrini-related cholangiocarcinoma.
Jusakul A; Kongpetch S; Teh BT
Curr Opin Gastroenterol; 2015 May; 31(3):258-63. PubMed ID: 25693006
[TBL] [Abstract][Full Text] [Related]
19. The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
Xu L; Wang L; Zhou L; Dorfman RG; Pan Y; Tang D; Wang Y; Yin Y; Jiang C; Zou X; Wu J; Zhang M
Neoplasia; 2019 May; 21(5):429-441. PubMed ID: 30933885
[TBL] [Abstract][Full Text] [Related]
20. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway.
Ma W; Han C; Zhang J; Song K; Chen W; Kwon H; Wu T
Hepatology; 2020 Oct; 72(4):1283-1297. PubMed ID: 31990985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
